Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation

ZYUS Life Sciences CEO Brent Zettl recently participated in a non-brokered private placement, acquiring additional common shares and warrants in the company. Despite this recent purchase, Zettl's overall ownership stake in ZYUS has significantly declined from 50.5% on a partially diluted basis in June 2023 to 44.3% as of the latest report. This reduction in his proportional holdings is primarily attributed to prior share dispositions and the expiration of unexercised warrants, signaling a notable shift in insider concentration.

Analysis

The President and CEO of ZYUS Life Sciences, Brent H. Zettl, participated in a June 2025 non-brokered private placement, acquiring 298,507 units at $0.67 each. While this purchase signals some insider confidence at the current valuation, the more significant development is the material decline in his overall ownership. Mr. Zettl's stake has fallen from a corrected 50.5% on a partially diluted basis in June 2023 to 44.3% at present, indicating he is no longer a majority holder on a diluted basis. This reduction was driven by two key prior events: a disposition of 470,000 shares in July 2024 to satisfy a $432,400 payment, suggesting a potential liquidity need, and the expiration of unexercised warrants in September 2024, which had a $3.55 exercise price, implying the stock was trading significantly below that level. The combination of a recent insider buy, a forced sale, and expired worthless warrants presents a mixed signal regarding the CEO's conviction and the company's performance.

Key Decisions for Investors

• Investors should interpret the CEO's recent share purchase cautiously, weighing this modest acquisition against the more significant trend of a 6.1 percentage point decrease in his partially diluted holdings over the last year.
• The disclosed reasons for past ownership reduction, including a share sale to cover payments and the expiration of out-of-the-money warrants, should be treated as potential red flags concerning insider liquidity and historical stock underperformance.
• The private placement price of $0.67 per share and the new warrant exercise price of $0.95 establish near-term valuation benchmarks and represent potential future shareholder dilution that should be incorporated into financial models.